All Insights White Paper Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

    Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

    Medicare Program

    Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

    Explore the potential alternatives Trump may pursue to reduce drug prices and what should pharma do in light of this policy reversal.

    Download White Paper
    Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

    The Trump administration announced earlier this year a proposal to eliminate rebates to PBMs in the Medicare and parts of the Medicaid programs effective January 1, 2020. The Trump administration made eliminating rebates a significant part of the American Patients First blueprint initiative launched in May 2018 to reduce out-of-pocket prescription drug costs. Most pharma experts predicted this rule change over time would lower out-of-pocket spending for patients, improve patient adherence to medicines with concomitant beneficial effects to health and economic outcomes, and increase pricing transparency in a part of the pharma sector that has remained very opaque. Then, the announcement in July 2019 that President Trump would not pursue implementation of this PBM rebate rule change. This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what should pharma companies do in light of this policy reversal.

    Contact us at insights@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Trumps Policy Rule Change on Ending Rebates to PBMs for the Medicare Program

    Blog

    Three Data Analytics Opportunities In Animal Health To Watch Out For

    Trumps Policy Rule Change on Ending Rebates to PBMs for the Medicare Program

    White Paper

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Trumps Policy Rule Change on Ending Rebates to PBMs for the Medicare Program

    White Paper

    Effects Of A Resurgence In COVID-19 Cases On Future Pharmaceutical Business Planning